Parkinson's Research In Metagenomic Early Stage Biomarkers
NCT ID: NCT07097103
Last Updated: 2025-07-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
80 participants
INTERVENTIONAL
2025-09-01
2029-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Targeting Diet-Microbiome Interactions in the Pathogenesis of Parkinson's Disease
NCT03705520
To Evaluate the Dose-response Effects of a Defined Volume of Physical Exercise on the Change of Peripheral Biomarkers, Clinical Response and Brain Connectivity in Parkinson's Disease: a Prospective, Observational, Cohort Pilot Study
NCT06339398
Microbiome and Diet in Parkinson's Disease
NCT06207136
Mediterranean Diet Effects on Parkinson's Disease
NCT06705517
Dietary Intervention and Gastrointestinal Function in Patients With Parkinson's Disease
NCT03851861
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Study presentation, selection and enrollment of patients;
* Evaluation of patients' health and nutritional status, including collection of physiological, pathological, and pharmacological history;
* Randomization of patients into four groups;
* Sample collection and storage;
* Microbiome analysis;
* Evaluation of motor and non-motor symptoms using clinical tests and rating scales at baseline (T0), at six months (T1) after treatment initiation, and at three and six months post-intervention (FU1 and FU2, respectively).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Mediterranean Diet Intervention (Group A)
Participants receive a structured Mediterranean Diet intervention, including personalized counseling, meal plans, educational sessions and monitoring.
Mediterranean Diet Intervention
Participants will follow a personalized diet plan over 24 weeks, based on the guidelines of the Mediterranean diet and defined according to their needs and the state of the disease; no food category will be excluded a priori. Individualized nutritional counseling and support materials (weekly meal plans, sample recipes, portion guides) will be provided by a qualified nutritionist. Adherence to the Mediterranean diet will be monitored periodically. Participants will maintain their usual diet during a pre-baseline period of at least 4 weeks, then switch to the Mediterranean plan under the supervision of a nutritionist.
Intensive Physical Activity Intervention (Group B)
Participants engage in a supervised structured physical activity program.
Intensive Physical Activity Intervention
Participants will perform exercise, over 24 weeks, according to WHO recommendations for adults, including those aged ≥ 64 years, to achieve at least 150-300 minutes of moderate-intensity aerobic physical activity, or at least 75-100 minutes of vigorous-intensity aerobic physical activity, or an equivalent combination of moderate and vigorous activity during the week. The WHO 2020 also recommend moderate-intensity or greater muscle-strengthening exercises involving alla major muscle groups for 2 or more days per week. Adherence will be monitored during in-person sessions and through wearable devices for activity tracking.
Mediterranean Diet + Intensive Physical Activity Combined Intervention (Group C=A+B)
Participants will receive both dietary and physical activity interventions.
Mediterranean Diet Intervention
Participants will follow a personalized diet plan over 24 weeks, based on the guidelines of the Mediterranean diet and defined according to their needs and the state of the disease; no food category will be excluded a priori. Individualized nutritional counseling and support materials (weekly meal plans, sample recipes, portion guides) will be provided by a qualified nutritionist. Adherence to the Mediterranean diet will be monitored periodically. Participants will maintain their usual diet during a pre-baseline period of at least 4 weeks, then switch to the Mediterranean plan under the supervision of a nutritionist.
Intensive Physical Activity Intervention
Participants will perform exercise, over 24 weeks, according to WHO recommendations for adults, including those aged ≥ 64 years, to achieve at least 150-300 minutes of moderate-intensity aerobic physical activity, or at least 75-100 minutes of vigorous-intensity aerobic physical activity, or an equivalent combination of moderate and vigorous activity during the week. The WHO 2020 also recommend moderate-intensity or greater muscle-strengthening exercises involving alla major muscle groups for 2 or more days per week. Adherence will be monitored during in-person sessions and through wearable devices for activity tracking.
Controls (Group D)
Participants continue their usual Parkinson's disease treatments according to clinical guidelines, without any additional specific dietary or exercise interventions provided by the study.
Control
Participants will continue their usual medical management for early Parkinson's disease according to current clinical guidelines, without any additional dietary or exercise interventions provided by the study, and will be monitored through standard follow-up visits but will not receive any study-specific dietary or physical activity programs.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mediterranean Diet Intervention
Participants will follow a personalized diet plan over 24 weeks, based on the guidelines of the Mediterranean diet and defined according to their needs and the state of the disease; no food category will be excluded a priori. Individualized nutritional counseling and support materials (weekly meal plans, sample recipes, portion guides) will be provided by a qualified nutritionist. Adherence to the Mediterranean diet will be monitored periodically. Participants will maintain their usual diet during a pre-baseline period of at least 4 weeks, then switch to the Mediterranean plan under the supervision of a nutritionist.
Intensive Physical Activity Intervention
Participants will perform exercise, over 24 weeks, according to WHO recommendations for adults, including those aged ≥ 64 years, to achieve at least 150-300 minutes of moderate-intensity aerobic physical activity, or at least 75-100 minutes of vigorous-intensity aerobic physical activity, or an equivalent combination of moderate and vigorous activity during the week. The WHO 2020 also recommend moderate-intensity or greater muscle-strengthening exercises involving alla major muscle groups for 2 or more days per week. Adherence will be monitored during in-person sessions and through wearable devices for activity tracking.
Control
Participants will continue their usual medical management for early Parkinson's disease according to current clinical guidelines, without any additional dietary or exercise interventions provided by the study, and will be monitored through standard follow-up visits but will not receive any study-specific dietary or physical activity programs.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* aged 35-80 years;
* Hoehn \& Yahr stage \> 1 and \< 3 in the clinical "ON" state;
* MoCA score ≥17.54;
* MMSE ≥24;
* Stable dopaminergic midication regimen for ≥ 4 weeks;
* Ability to interact with the research team and provide informed consent in Italian;
* Suitable to physical exercise;
* Able to walk unassisted (no walking aids);
* Willingness and ability to comply with all study procedures;
* Willingness to maintain usual diet during a ≥ 4-week pre-baseline period;
* Willingness to switch to a Mediterranean-style diet during the intervention;
* Ability to provide stool samples at each collection timepoint;
* Willing to avoid strenuous exercise and alcohol for 24 hours prior to each visits.
Exclusion Criteria
* Atypical or secondary Parkinsonism;
* Presence of pacemakers or other subcutaneous electronic devices;
* Any other neurological or neurodegenerative disorders;
* Moderate to severe cognitive decline;
* Beck Depression Inventory-II (BDI-II)\] score ≥28;
* Dementia diagnosis;
* Thyroid dysfunctions;
* Type1 Diabetes Mellitus;
* Type 2 diabetes mellitus with HbA₁c ≥ 8% or on insulin therapy;
* Acute diseases;
* Active Neoplasia;
* IBD or IBS;
* Celiac disease;
* History of major gastrointestinal surgery or acute GI conditions (e.g., gastroenteritis) within the past 3-6 months;
* Chronic corticosteroid therapy;
* Use of proton pump inhibitors within the past 30 days;
* Acute, antibiotic-resistant infections;
* Antibiotic intake within the past 30 days;
* Prebiotic/probiotic supplement use in the past 30 days;
* Prolonged intake of anxiolytic drugs, antidepressants, antipsychotics, cognitive stimulants, and analogs in the past 3 months;
* Underweight (BMI \<18.5);
* History of deep brain stimulation (DBS) surgery;
* Pregnancy or lactation;
* Regular use of enemas or suppositories to alleviate constipation;
* Use of experimental products in the 3 months prior to the screening visit
* Patients who, for medical reasons, are required to follow special dietary regimens that could interfere with the adoption or effectiveness of the Mediterranean model;
* Vegan/Vegetarian diet or any other dietary behaviour that excludes one or more of the typical food groups of the Mediterranean model.
35 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
San Raffaele Cassino, Cassino, Italy
UNKNOWN
IRCCS San Raffaele Roma
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RP 340/SR/25
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.